More results...

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors



Mounjaro: New weight loss drug approved for use in Britain to be available ‘within weeks’

Healthcare Jan 29, 2024 at 13:37

Mounjaro: New weight loss drug approved for use in Britain to be available 'within weeks'

The active ingredient in the drug helps to reduce sugar levels in people with type 2 diabetes when their levels are high, and works as a weight management drug by making a patient feel full, and making them experience fewer food cravings.

An American weight loss drug approved in a four-dose injection pen format for use in Britain could be available “within weeks”.

Mounjaro, also known as tirzepatide, is a diabetes drug that was authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) to help obese and overweight adults lose and manage weight in November last year.

The authorisation of the US pharmaceutical company Eli Lilly’s Mounjaro “KwikPen” means the company will be able to “begin supply to the UK within weeks”, according to its president and general manager of UK and Northern Europe Laura Steele.

The Mounjaro KwikPen gives four doses of the drug for once-a-week treatment over a month, and has been approved to treat adults with type 2 diabetes and for weight management in obese adults, as well as overweight adult patients who have weight-related health problems like prediabetes, high blood pressure, high cholesterol, or heart problems.

Julian Beach, MHRA interim executive director of healthcare quality and access, said: “The public health importance of safe and effective treatments to help manage diabetes and obesity,  which can have a significant impact on people’s health, is clear.

“This approval enables access to the approved Mounjaro pen in a more convenient presentation of a month’s treatment, of one dose per week.”

The jab was approved for  NHS use in September last year by the National Institute for Health and Care Excellence (NICE) as an option for patients with type 2 diabetes who do not have the condition under control, but NICE has yet to approve use of the drug for obesity.